MetaVia Regains Nasdaq Compliance with Minimum Bid Price Requirement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Compliance Restoration: On December 19, 2025, MetaVia received formal notice from Nasdaq confirming its compliance with the minimum bid price requirement, indicating resolution of listing issues and enhancing investor confidence in the company.
- Clinical Advancements: The development of DA-1726 shows best-in-class potential for weight loss, glucose control, and waist reduction, highlighting the company's innovative capabilities in obesity treatment, which may attract increased investor interest in its clinical trial progress.
- New Drug Development: Vanoglipel demonstrated positive effects on liver inflammation and lipid metabolism in pre-clinical studies, and its direct hepatic action was confirmed in a Phase 2a clinical study, potentially providing strong support for the company's future market competitiveness.
- Market Positioning: With a focus on transforming cardiometabolic diseases, MetaVia's expanding product pipeline is expected to further solidify its market position in the biotechnology sector, attracting more investors interested in cardiometabolic disease solutions.
MTVA
$8.73+Infinity%1D
Analyst Views on MTVA
Wall Street analysts forecast MTVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MTVA is 9.67 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.620
Low
5.00
Averages
9.67
High
12.00
Current: 8.620
Low
5.00
Averages
9.67
High
12.00
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
